MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 528820 | Name: SG-2000

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SG-2000 is a DNA-intercalating agent potentially for the treatment of ovarian cancer and leukemia.

Chemical Structure

SG-2000
SG-2000
CAS#232931-57-6

Theoretical Analysis

MedKoo Cat#: 528820

Name: SG-2000

CAS#: 232931-57-6

Chemical Formula: C31H32N4O8

Exact Mass: 588.2220

Molecular Weight: 588.61

Elemental Analysis: C, 63.26; H, 5.48; N, 9.52; O, 21.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SG-2000; BN-2629; NSC-694501; NSC-D-694501; SJG-136; UP-2001; NSCD-694501; SG2000; BN2629; NSC694501; NSCD694501; SJG136; UP2001; NSCD694501; SG 2000; BN 2629; NSC 694501; NSC D 694501; SJG 136; UP 2001; NSCD 694501
IUPAC/Chemical Name
1,1'-(propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione)
InChi Key
BJSOOANQHCJYPG-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H32N4O8/c1-16-14-34-24(28(36)32-22-8-6-18(40-3)12-20(22)30(34)38)26(16)42-10-5-11-43-27-17(2)15-35-25(27)29(37)33-23-9-7-19(41-4)13-21(23)31(35)39/h6-9,12-13,24-27H,1-2,5,10-11,14-15H2,3-4H3,(H,32,36)(H,33,37)
SMILES Code
O=C1N2C(C(OCCCOC(C(N3C4)C(NC5=CC=C(OC)C=C5C3=O)=O)C4=C)C(C2)=C)C(NC6=CC=C(OC)C=C16)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 588.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mellinas-Gomez M, Spanswick VJ, Paredes-Moscosso SR, Robson M, Pedley RB, Thurston DE, Baines SJ, Stell A, Hartley JA. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Vet Res. 2015 Aug 19;11:215. doi: 10.1186/s12917-015-0534-2. PubMed PMID: 26282406; PubMed Central PMCID: PMC4539724. 2: Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res. 2013 Feb 1;19(3):721-30. doi: 10.1158/1078-0432.CCR-12-2529. Epub 2012 Dec 18. PubMed PMID: 23251007. 3: Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs. 2011 Jun;20(6):733-44. doi: 10.1517/13543784.2011.573477. Epub 2011 Apr 4. Review. PubMed PMID: 21457108. 4: Hartley JA, Hochhauser D. Small molecule drugs - optimizing DNA damaging agent-based therapeutics. Curr Opin Pharmacol. 2012 Aug;12(4):398-402. doi: 10.1016/j.coph.2012.03.008. Epub 2012 Apr 11. Review. PubMed PMID: 22503290. 5: Reid JM, Buhrow SA, Kuffel MJ, Jia L, Spanswick VJ, Hartley JA, Thurston DE, Tomaszewski JE, Ames MM. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. Cancer Chemother Pharmacol. 2011 Sep;68(3):777-86. doi: 10.1007/s00280-010-1517-4. Epub 2010 Dec 28. PubMed PMID: 21188379. 6: Hartley JA, Hamaguchi A, Suggitt M, Gregson SJ, Thurston DE, Howard PW. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Invest New Drugs. 2012 Jun;30(3):950-8. doi: 10.1007/s10637-011-9647-z. Epub 2011 Mar 8. PubMed PMID: 21384134. 7: Hartley JA, Hamaguchi A, Coffils M, Martin CR, Suggitt M, Chen Z, Gregson SJ, Masterson LA, Tiberghien AC, Hartley JM, Pepper C, Lin TT, Fegan C, Thurston DE, Howard PW. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. Cancer Res. 2010 Sep 1;70(17):6849-58. doi: 10.1158/0008-5472.CAN-10-0790. Epub 2010 Jul 26. PubMed PMID: 20660714; PubMed Central PMCID: PMC3533126. 8: Mantaj J, Jackson PJ, Rahman KM, Thurston DE. From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). Angew Chem Int Ed Engl. 2017 Jan 9;56(2):462-488. doi: 10.1002/anie.201510610. Epub 2016 Nov 15. Review. PubMed PMID: 27862776; PubMed Central PMCID: PMC5215561. 9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183.